GOT1, glutamic-oxaloacetic transaminase 1, 2805

N. diseases: 71; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 Biomarker group BEFREE A CRC subcutaneous tumor model was performed to determine the impact of GOT1 inhibition on 5-FU efficacy in vivo. 28314989 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 Biomarker group BEFREE Shorter overall survival was associated with high expression of GLUT1 in tumor (P = 0.002) and GOT1 in tumor (p = 0.030). 25719198 2015
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors 		0.040 Biomarker group BEFREE Human neuroendocrine tumor cell lines from the pancreas (BON1), lung (NCI-H727), and midgut (GOT1) were incubated with the MDM2 inhibitor NVP-CGM097 (Novartis) at concentrations from 4 to 2,500 nM. 27871087 2018
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors 		0.040 GeneticVariation group BEFREE The aims of the study were to identify and elucidate possible optimization venues for <sup>177</sup>Lu[Lu]-octreotate tumor therapy by characterizing transcriptional responses in the GOT1 small intestine neuroendocrine tumor model in nude mice. 29502008 2018
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors 		0.040 Biomarker group BEFREE Hedgehog inhibitor sonidegib potentiates <sup>177</sup>Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. 28789624 2017
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors 		0.040 Biomarker group BEFREE Priming increases the anti-tumor effect and therapeutic window of <sup>177</sup>Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1. 28097640 2017
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.030 Biomarker disease BEFREE A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth. 31787239 2020
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.030 Biomarker disease BEFREE A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth. 31787239 2020
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.030 AlteredExpression disease BEFREE Collectively, this study suggested that miR-9-5p regulates GOT1 expression in pancreatic cancer, thereby stunting proliferation, invasion, glutamine metabolism and redox homeostasis, and that miR-9-5p may serve as a prognostic or therapeutic target for pancreatic cancer. 30591220 2019
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.030 AlteredExpression disease BEFREE Collectively, this study suggested that miR-9-5p regulates GOT1 expression in pancreatic cancer, thereby stunting proliferation, invasion, glutamine metabolism and redox homeostasis, and that miR-9-5p may serve as a prognostic or therapeutic target for pancreatic cancer. 30591220 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.030 Biomarker disease BEFREE As such, small molecule inhibitors that target GOT1 could serve as starting points for the development of new therapies for pancreatic cancer. 30365304 2018
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.030 Biomarker disease BEFREE As such, small molecule inhibitors that target GOT1 could serve as starting points for the development of new therapies for pancreatic cancer. 30365304 2018
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.020 Biomarker disease BEFREE Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism. 31470862 2019
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.020 Biomarker disease BEFREE GOT1 was silenced in several PDAC cell lines. 31470862 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 AlteredExpression disease BEFREE Analysis of enzymes that mediate the conversion of glutamate to AKG shows that TAZ/YAP induce glutamic-oxaloacetic transaminase (GOT1) and phosphoserine aminotransferase (PSAT1) expression and that TAZ/YAP activity positively correlates with transaminase expression in breast cancer patients. 29661856 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 AlteredExpression disease BEFREE High levels of GOT1 were further linked to poor survival as analysed by the GEPIA web tool, in thyroid and breast carcinoma and in lung adenocarcinoma. 29751795 2018
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.020 Biomarker disease BEFREE Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. 29731362 2018
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.020 Biomarker disease BEFREE Recently, it has been demonstrated that PDAC tumors are dependent upon a metabolic pathway involving aspartate aminotransferase 1, also known as glutamate-oxaloacetate transaminase 1 (GOT1), for the maintenance of redox homeostasis and sustained proliferation. 29731362 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.020 GeneticVariation disease BEFREE A gene variation (rs12691) in the CCAT/enhancer binding protein α modulates glucose metabolism in metabolic syndrome. 22269963 2013
CUI: C2347761
Disease: Childhood Myelodysplastic Syndrome
Childhood Myelodysplastic Syndrome 		0.020 GeneticVariation disease BEFREE We reported a second case of t(10;12)-positive myelodysplastic syndrome in whom fluorescent in situ hybridization confirmed the non-random translocation but molecular biology analyses revealed a ETV6/GOT1 chimera varying from the first case described. 18310541 2008
CUI: C3463824
Disease: MYELODYSPLASTIC SYNDROME
MYELODYSPLASTIC SYNDROME 		0.020 GeneticVariation group BEFREE We reported a second case of t(10;12)-positive myelodysplastic syndrome in whom fluorescent in situ hybridization confirmed the non-random translocation but molecular biology analyses revealed a ETV6/GOT1 chimera varying from the first case described. 18310541 2008
CUI: C3900098
Disease: Adult Myelodysplastic Syndrome
Adult Myelodysplastic Syndrome 		0.020 GeneticVariation disease BEFREE We reported a second case of t(10;12)-positive myelodysplastic syndrome in whom fluorescent in situ hybridization confirmed the non-random translocation but molecular biology analyses revealed a ETV6/GOT1 chimera varying from the first case described. 18310541 2008
CUI: C2347761
Disease: Childhood Myelodysplastic Syndrome
Childhood Myelodysplastic Syndrome 		0.020 Biomarker disease BEFREE This work identifies GOT1 as a novel fusion partner of ETV6 in myelodysplastic syndrome. 16757412 2006
CUI: C3463824
Disease: MYELODYSPLASTIC SYNDROME
MYELODYSPLASTIC SYNDROME 		0.020 Biomarker group BEFREE This work identifies GOT1 as a novel fusion partner of ETV6 in myelodysplastic syndrome. 16757412 2006
CUI: C3900098
Disease: Adult Myelodysplastic Syndrome
Adult Myelodysplastic Syndrome 		0.020 Biomarker disease BEFREE This work identifies GOT1 as a novel fusion partner of ETV6 in myelodysplastic syndrome. 16757412 2006